Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.77 |
| ▸ | JAK1 | P23458 | 13/20 | 0.77 |
| ▸ | JAK3 | P52333 | 3/20 | 0.73 |
| ▸ | TYK2 | P29597 | 3/20 | 0.71 |
| ▸ | IKBKB | O14920 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.71 |
| ▸ | SYK | P43405 | 1/20 | 0.71 |
| ▸ | GSK3B | P49841 | 1/20 | 0.71 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185993 | 0.87 | JAK2 (0.82) | JAK2JAK1JAK3TYK2IKBKB | |
| SCHEMBL2237531 | 0.87 | JAK2 (1.00) | JAK2JAK1JAK3TYK2IKBKB | |
| SCHEMBL11916701 | 0.87 | JAK1 (1.00) | JAK2JAK1JAK3TYK2IKBKB | |
| SCHEMBL13031676 | 0.86 | JAK2 (0.70) | JAK2JAK1JAK3TYK2IKBKB | |
| SCHEMBL13031299 | 0.86 | JAK2 (0.80) | JAK2JAK1JAK3TYK2IKBKB | |
| SCHEMBL13031260 | 0.86 | JAK1 (1.00) | JAK2JAK1JAK3TYK2IKBKB | |
| SCHEMBL7960595 | 0.86 | JAK2 (0.80) | JAK2JAK1JAK3TYK2IKBKB | |
| SCHEMBL13031226 | 0.86 | JAK2 (0.82) | JAK2JAK1JAK3TYK2IKBKB | |
| SCHEMBL7963625 | 0.86 | JAK2 (0.80) | JAK2JAK1JAK3TYK2IKBKB | |
| SCHEMBL2238602 | 0.86 | JAK2 (0.80) | JAK2JAK1JAK3TYK2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2021-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | JAK2 5/4885JAK1 2/4885JAK3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.